Tianjin Tasly Zhijiao Pharmaceutical

Tianjin Tasly Zhijiao Pharmaceutical is a core subsidiary of the Tasly Pharmaceutical Group, specializing in the research, development, and manufacturing of modern Traditional Chinese Medicine (TCM) injections. The company is particularly recognized for its expertise in cardiovascular and cerebrovascular therapeutic areas, with a flagship product being the Dengzhan Xixin (Erigeron Breviscapus) injection. Operating out of Tianjin, China, the firm utilizes advanced extraction and purification technologies to standardize TCM products for clinical use. Its facilities are GMP-certified, supporting large-scale production of sterile injections and other pharmaceutical forms. As a leader in the modernization of herbal medicine, Tasly Zhijiao integrates traditional knowledge with rigorous scientific validation. The company plays a vital role in the parent group's strategy to globalize Chinese pharmaceutical products.